ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00796445
Recruitment Status : Terminated (The study was terminated early following assessment of the two co-primary endpoints showing the lack of efficacy of the study product.)
First Posted : November 24, 2008
Last Update Posted : September 30, 2016
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Terminated
  Actual Primary Completion Date : September 2015
  Actual Study Completion Date : January 2016
  Certification/Extension First Submitted : November 16, 2012

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 30, 2016
November 22, 2016